Literature DB >> 667870

QRS voltage change with adriamycin administration.

R A Minow, R S Benjamin, E T Lee, J A Gottlieb.   

Abstract

A decrease in the electrocardiographic limb lead QRS voltage of greater than or equal to 30% was highly correlated with the development of congestive heart failure in patients treated with adriamycin (ADM). It is felt that if a decrease in limb lead QRS voltage greater than or equal to 30% were detected in a patient receiving ADM, cardiomyopathy might be avoided or ameliorated by discontinuation of the drug.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 667870

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  5 in total

1.  A phase-II clinical trial of 4'-epi-doxorubicin in advanced solid tumors.

Authors:  A Martoni; M Giovannini; L Tomasi; C M Camaggi; B Bellanova; N Monetti; G Rossini; M Tarquinii; A Martini; F Pannuti
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

2.  Assessment of adriamycin cardiotoxicity in children by systolic time intervals.

Authors:  H E Ulmer; R Ludwig; H Geiger
Journal:  Eur J Pediatr       Date:  1979-04-25       Impact factor: 3.183

Review 3.  Adriamycin (doxorubicin) cardiotoxicity: a review.

Authors:  R T Chlebowski
Journal:  West J Med       Date:  1979-11

Review 4.  Doxorubicin (adriamycin) cardiomyopathy.

Authors:  E Saltiel; W McGuire
Journal:  West J Med       Date:  1983-09

5.  Scintigraphic evaluation of myocardial uptake of thallium 201 and technetium 99m pyrophosphate utilizing a rat model of chronic doxorubicin cardiotoxicity.

Authors:  M Miyagawa; S Tanada; K Hamamoto
Journal:  Eur J Nucl Med       Date:  1991
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.